Skip to main content
. Author manuscript; available in PMC: 2020 Dec 1.
Published in final edited form as: J Thorac Oncol. 2019 Aug 27;14(12):2152–2163. doi: 10.1016/j.jtho.2019.08.009

Figure 3.

Figure 3.

(A-C)Immunocompetent mice bearing bladder cancer tumors MBT-2 (A), colon cancer tumors MC38 (B), and pancreatic cancer tumors Pan02 (C) on their flanks were treated with vehicle, SRA737 (100mg/kg; 5/7 days), anti-PD1 (10mg/kg; BIW i.p.) or their combination. Tumor growth curves are shown as mean tumor volumes +/− SEM. **p<0.01.

(D-E)Nanostring analysis of CXCL10 and CCL5 mRNA expression in MBT-2 tumors resected after 7 or 14 days of treatment with SRA737 (100 mg/kg; 5/7 days). Data presented as mean ± SD and p values by t-test **p<0.01.

(F) Quantification of CD4+ and CD8+ IHC staining in tumors resected from MC38 colon model, following 14 days of treatment with a modified treatment schedule of SRA737 (100mg/kg; 7 days on/ 7 days off) +/− anti-PD-1 (10mg/kg; day 3,7 and 11).

HHS Vulnerability Disclosure